The DUSP23 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting DUSP23 in the A2780 human ovarian carcinoma line. This polyclonal pool offers a heterogeneous loss-of-function model for pooled analyses without single-cell cloning.
The A2780 cell line was established from an untreated patient with ovarian carcinoma and is widely used as an in vitro model for high-grade serous ovarian cancer, the most prevalent and lethal form of ovarian malignancy. A2780 cells maintain epithelial morphology and key molecular features of the original tumor, including sensitivity to platinum agents, making them an invaluable platform for investigating mechanisms of chemoresistance and dissecting signal transduction pathways underpinning ovarian cancer progression.
DUSP23 is a dual-specificity phosphatase that negatively regulates stress-activated MAP kinases by dephosphorylating JNK and p38. Upon activation by MAP3Ks like MEKK1 and ASK1, oxidative stress, or growth factor receptors, DUSP23 dephosphorylates phosphothreonine and phosphotyrosine residues within the TXY motifs of JNK1/2/3 and p38 alpha, terminating their kinase activity. This reduces phosphorylation of downstream targets c-Jun and ATF2, attenuating AP-1-dependent transcription. DUSP23 interacts directly with JNKs and p38 alpha, and scaffold proteins such as JIP modulate its localization and function, thus precisely controlling signal duration and cellular outcomes like proliferation and apoptosis.
Within the A2780 ovarian cancer context, disruption of DUSP23 eliminates a critical brake on stress-activated MAPK cascades, leading to heightened and prolonged JNK and p38 signaling upon stimulation. This model is particularly relevant given the frequent aberrant activation of MAPK pathways in high-grade serous ovarian cancer and their association with resistance to platinum-based chemotherapy. By comparing wild-type and DUSP23-knockout A2780 cells, researchers can interrogate how sustained JNK/p38 activity influences cellular responses to genotoxic chemotherapeutics like cisplatin and clarify whether DUSP23 functions as a tumor suppressor or a mediator of adaptive survival pathways that promote drug tolerance.
This polyclonal knockout cell population supports a broad range of experimental applications, including analysis of MAPK signaling dynamics through phospho-specific western blotting for JNK and p38, transcriptional profiling of downstream effectors by RT-qPCR, and pathway output quantification using AP-1?Cluciferase reporter assays. Functional studies employing cisplatin dose-response viability assays and Annexin V apoptosis detection by flow cytometry are ideally suited to evaluate the role of DUSP23 in chemosensitivity. Additionally, these cells constitute a robust system for screening small-molecule kinase inhibitors targeting the JNK/p38 axis and for exploring the interplay between phosphatase activity and oncogenic signaling networks in ovarian cancer. For further information, please contact Ascent Research.
